Revenue Update on Champions Oncology Inc(NASDAQ:CSBR)

Champions Oncology Inc(NASDAQ:CSBR) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-market on Jul 28, 2016. Earnings per share were $-0.24.

Several Insider Transactions has been reported to the SEC. On Mar 17, 2015, Ronnie Morris (President) purchased 2,710,526 shares at $0.00 per share price.Also, On Mar 17, 2015, Joel Ackerman (CEO) purchased 2,710,526 shares at $0.00 per share price.On Mar 17, 2015, Daniel Newman Mendelson (director) purchased 750,000 shares at $0.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Champions Oncology Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The Company’s POS business provides services to physicians and patients looking for information to help guide the development of personalized treatment plans. The Company’s TOS business provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The Company’s TumorGraft Technology Platform consists of processes physical tumors and information that it uses to personalize the development and use of oncology drugs.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Champions Oncology Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Champions Oncology Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.